A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer
- Stephen R.D. Johnston*
- , Henry Gómez
- , Salomon M. Stemmer
- , Maria Richie
- , Michael Durante
- , Lini Pandite
- , Vicki Goodman
- , Dennis Slamon
*Corresponding author for this work
- Institute of Cancer Research
- Instituto Nacional de Enfermedades Neoplasicas
- Rabin Medical Center Israel
- GlaxoSmithKline
- University of California at Los Angeles
Research output: Contribution to journal › Article › peer-review
42
Scopus
citations